Medical Condition

breast cancer

Total Trials

38

Recruiting Now

38

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

Breast cancer trials cover the full spectrum of disease — from ductal carcinoma in situ (DCIS) to metastatic HER2-positive and triple-negative subtypes — with an emphasis on biomarker-driven patient selection. Neoadjuvant approaches that shrink tumors before surgery and adjuvant therapies that reduce recurrence risk are active areas of investigation, alongside novel agents targeting PI3K, CDK4/6, and PARP pathways.

Current trials test CDK4/6 inhibitors, HER2-targeted combinations, PARP inhibitors for BRCA1/2 carriers, immunotherapy in triple-negative breast cancer, and endocrine therapies for hormone-receptor-positive disease. Trials also study de-escalation strategies to reduce overtreatment in low-risk early-stage patients.

Eligibility often depends on hormone receptor (HR) and HER2 status, BRCA mutation status, and prior treatment history.

Frequently Asked Questions — breast cancer Clinical Trials

How many clinical trials are currently recruiting for breast cancer?

ClinicalMetric currently tracks 38 actively recruiting clinical trials for breast cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 38. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for breast cancer?

breast cancer research spans Phase 1 (8 trials), Phase 2 (7 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a breast cancer clinical trial?

Eligibility criteria for breast cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

UNC Lineberger Comprehensive Cancer Center 3 trials

Dana-Farber Cancer Institute 2 trials

European Institute of Oncology 2 trials

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 trial

Shanghai Best-Link Bioscience, LLC 1 trial

breast cancer

Frequently Asked Questions — breast cancer Clinical Trials

Recruiting Clinical Trials

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?

A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer

A Novel Approach Utilizing Organ Specific Age Proteomics

Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device

Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients

To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.

The COMPASSION Study

Sample Collection for Ongoing Research and Product Evaluation Study

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer

UNC Pleural Fluid Registry

Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes

UCF MammoChat: Image Repository

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

RADIOSO MILAN I (RADar Reflector localisatiOn-SCOUT for carcinOma Mammae, the MILAN IEO Experience I)

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Observation of Exhaled VOC Biomarkers Characteristics in Admitted Women with Breast Ultrasound BI-RADS 4 Grade

Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Axelopran for Advanced Cancer in Patients Receiving Opioids

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NeoRad Breast Cancer Study

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Omission of SLNB in CN0 Early Breast Cancer

Precise Oncology Interventions in Nutrition and Training (OnPoint)

Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

3D-printed Biodegradable Breast Implants for Breast Restoration